Decreasing incidence of symptomatic epstein-barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: Report of the studies of pediatric liver transplantation experience

Liver Transplantation

Volumn 19, Issue 7, 2013, Pages 730-740

  Narkewicz, Michael R ^a,b   Green, Michael ^c,d   Dunn, Stephen ^e,f   Millis, Michael ^g   McDiarmid, Susan ^h,i   Mazariegos, George ^c,d   Anand, Ravinder ^j   Yin, Wanrong ^j  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^j EMMES CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; STEROID; TACROLIMUS;

ARTICLE; BILE DUCT ATRESIA; CHILD; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATIC EPSTEIN BARR VIRUS INFECTION;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RISK FACTORS;

EID: 84879516415     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23659     Document Type: Article

References (21)

1. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-529.
2. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75: 987-993.
3. Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438-1442.
4. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375.
5. Cacciarelli TV, Reyes J, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Green M,. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001; 5: 359-364.
6. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME,. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-99.
7. Tsao L, Hsi ED,. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007; 131: 1209-1218.
8. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM,. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6 (pt 1): 1017-1024.
9. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-727.
10. Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3: 22-26.
11. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
12. Holmes RD, Sokol RJ,. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464.
13. Otte JB,. History of pediatric liver transplantation. Where are we coming from? Where do we stand? Pediatr Transplant 2002; 6: 378-387.
14. Gridelli B, Spada M, Riva S, Colledan M, Segalin A, Lucianetti A, et al. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation. Transpl Int 2000; 13 (suppl 1): S399-S401.
15. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611.
16. Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906-1912.
17. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228.
18. SPLIT Research Group. Studies of Pediatric Liver Transplantation (SPLIT): year 2000 outcomes. Transplantation 2001; 72: 463-476.
19. Harris NL, Swerdlow SH, Frizzera G, Knowles DM,. Post-transplant lymphoproliferative disorders. In:, Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (World Health Organization Classification of Tumors). Lyon, France: IARC Press; 2001: 264-269.
20. Shepherd RW, Turmelle Y, Nadler M, Lowell JA, Narkewicz MR, McDiarmid SV, et al.; for SPLIT Research Group. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008; 8: 396-403.
21. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ,. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367-372. Kidney Diseases